Intramyocardial Transplantation of Umbilical Cord Mesenchymal Stromal Cells in Chronic Ischemic Cardiomyopathy: A Controlled, Randomized Clinical Trial (HUC-HEART Trial

Creative Commons License

Ulus A. T., Mungan C., Kurtoglu M., TOPAL ÇELİKKAN F., AKYOL M., Sucu M., ...More

INTERNATIONAL JOURNAL OF STEM CELLS, vol.13, no.3, pp.364-376, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 3
  • Publication Date: 2020
  • Doi Number: 10.15283/ijsc20075
  • Journal Name: INTERNATIONAL JOURNAL OF STEM CELLS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE
  • Page Numbers: pp.364-376
  • Keywords: Bone marrow MSC, Clinical trial, Ischemic cardiomyopathy, Stem cell therapy, Umbilical cord MSC, STEM-CELLS, INTRACORONARY INFUSION, HEART-FAILURE, PHASE 1/2, REGENERATION, PERFUSION, EFFICACY, SAFETY
  • Ankara University Affiliated: Yes

Abstract

Background and Objectives: The HUG-HEART Trial (ClinicalTrials.gov Identifier: NCT02323477) was a controlled, prospective, phase VII, multicenter, single-blind, three-arm randomized study of intramyocardial deliver of human umbilical cord-derived mesenchymal stromal cells (HUC-MSCs) combined with coronary artery bypass-grafting (CABG) n patients with chronic ischemic cardiomyopathy (CIC). The trial aimed to assess (i) the safety and the efficacy of cell transplantation during one-year follow-up, (ii) to compare the efficacy of HUC-MSCs with autologous bone-marrow-derived mononuclear cells (BM-MNCs) in the same clinical settings.